These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 30446386)

  • 1. Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function.
    Buchan SL; Dou L; Remer M; Booth SG; Dunn SN; Lai C; Semmrich M; Teige I; Mårtensson L; Penfold CA; Chan HTC; Willoughby JE; Mockridge CI; Dahal LN; Cleary KLS; James S; Rogel A; Kannisto P; Jernetz M; Williams EL; Healy E; Verbeek JS; Johnson PWM; Frendéus B; Cragg MS; Glennie MJ; Gray JC; Al-Shamkhani A; Beers SA
    Immunity; 2018 Nov; 49(5):958-970.e7. PubMed ID: 30446386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.
    Hernandez-Chacon JA; Li Y; Wu RC; Bernatchez C; Wang Y; Weber JS; Hwu P; Radvanyi LG
    J Immunother; 2011 Apr; 34(3):236-50. PubMed ID: 21389874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy.
    Chacon JA; Wu RC; Sukhumalchandra P; Molldrem JJ; Sarnaik A; Pilon-Thomas S; Weber J; Hwu P; Radvanyi L
    PLoS One; 2013; 8(4):e60031. PubMed ID: 23560068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 4-1BB Agonism Combined With PD-L1 Blockade Increases the Number of Tissue-Resident CD8+ T Cells and Facilitates Tumor Abrogation.
    Qu QX; Zhu XY; Du WW; Wang HB; Shen Y; Zhu YB; Chen C
    Front Immunol; 2020; 11():577. PubMed ID: 32391001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity.
    Compte M; Harwood SL; Muñoz IG; Navarro R; Zonca M; Perez-Chacon G; Erce-Llamazares A; Merino N; Tapia-Galisteo A; Cuesta AM; Mikkelsen K; Caleiras E; Nuñez-Prado N; Aznar MA; Lykkemark S; Martínez-Torrecuadrada J; Melero I; Blanco FJ; Bernardino de la Serna J; Zapata JM; Sanz L; Alvarez-Vallina L
    Nat Commun; 2018 Nov; 9(1):4809. PubMed ID: 30442944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 4-1BB Delineates Distinct Activation Status of Exhausted Tumor-Infiltrating CD8
    Kim HD; Park S; Jeong S; Lee YJ; Lee H; Kim CG; Kim KH; Hong SM; Lee JY; Kim S; Kim HK; Min BS; Chang JH; Ju YS; Shin EC; Song GW; Hwang S; Park SH
    Hepatology; 2020 Mar; 71(3):955-971. PubMed ID: 31353502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-talk between 4-1BB and TLR1-TLR2 Signaling in CD8+ T Cells Regulates TLR2's Costimulatory Effects.
    Joseph AM; Srivastava R; Zabaleta J; Davila E
    Cancer Immunol Res; 2016 Aug; 4(8):708-16. PubMed ID: 27267778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses.
    Shuford WW; Klussman K; Tritchler DD; Loo DT; Chalupny J; Siadak AW; Brown TJ; Emswiler J; Raecho H; Larsen CP; Pearson TC; Ledbetter JA; Aruffo A; Mittler RS
    J Exp Med; 1997 Jul; 186(1):47-55. PubMed ID: 9206996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Marked expansion of CD11c+CD8+ T-cells in melanoma-bearing mice induced by anti-4-1BB monoclonal antibody.
    Ju SA; Park SM; Lee SC; Kwon BS; Kim BS
    Mol Cells; 2007 Aug; 24(1):132-8. PubMed ID: 17846508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Remodeling of the tumor microenvironment via disrupting Blimp1
    Dixon ML; Luo L; Ghosh S; Grimes JM; Leavenworth JD; Leavenworth JW
    Mol Cancer; 2021 Nov; 20(1):150. PubMed ID: 34798898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target.
    Freeman ZT; Nirschl TR; Hovelson DH; Johnston RJ; Engelhardt JJ; Selby MJ; Kochel CM; Lan RY; Zhai J; Ghasemzadeh A; Gupta A; Skaist AM; Wheelan SJ; Jiang H; Pearson AT; Snyder LA; Korman AJ; Tomlins SA; Yegnasubramanian S; Drake CG
    J Clin Invest; 2020 Mar; 130(3):1405-1416. PubMed ID: 32015231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity.
    Qi X; Li F; Wu Y; Cheng C; Han P; Wang J; Yang X
    Nat Commun; 2019 May; 10(1):2141. PubMed ID: 31105267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intratumoral CD8
    Horton BL; Williams JB; Cabanov A; Spranger S; Gajewski TF
    Cancer Immunol Res; 2018 Jan; 6(1):14-24. PubMed ID: 29097422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunity to melanoma mediated by 4-1BB is associated with enhanced activity of tumour-infiltrating lymphocytes.
    Ju SA; Lee SC; Kwon TH; Heo SK; Park SM; Paek HN; Suh JH; Cho HR; Kwon B; Kwon BS; Kim BS
    Immunol Cell Biol; 2005 Aug; 83(4):344-51. PubMed ID: 16033529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 4-1BB signaling breaks the tolerance of maternal CD8+ T cells that are reactive with alloantigens.
    Kim KH; Choi BK; Kim JD; Kim YH; Lee SK; Suh JH; Lee SC; Kang SW; Kwon BS
    PLoS One; 2012; 7(9):e45481. PubMed ID: 23029041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy.
    Cannons JL; Lau P; Ghumman B; DeBenedette MA; Yagita H; Okumura K; Watts TH
    J Immunol; 2001 Aug; 167(3):1313-24. PubMed ID: 11466348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dispensable role for 4-1BB and 4-1BBL in development of vaccinia virus-specific CD8 T cells.
    Zhao Y; Croft M
    Immunol Lett; 2012 Jan; 141(2):220-6. PubMed ID: 22037570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody.
    Ha D; Tanaka A; Kibayashi T; Tanemura A; Sugiyama D; Wing JB; Lim EL; Teng KWW; Adeegbe D; Newell EW; Katayama I; Nishikawa H; Sakaguchi S
    Proc Natl Acad Sci U S A; 2019 Jan; 116(2):609-618. PubMed ID: 30587582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment.
    Williams JB; Horton BL; Zheng Y; Duan Y; Powell JD; Gajewski TF
    J Exp Med; 2017 Feb; 214(2):381-400. PubMed ID: 28115575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner.
    Miller RE; Jones J; Le T; Whitmore J; Boiani N; Gliniak B; Lynch DH
    J Immunol; 2002 Aug; 169(4):1792-800. PubMed ID: 12165501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.